

---

## Review Tool reports

### UNDERSTANDING AND CONTEXTUALIZING THE REPORTS

Readers of these automated manuscript Review Tool reports are encouraged to use them to support them in performing their own assessment and 'health check' on a preprint prior to it completing peer review.

However, these should only be used as a guide, read within the overall context of the article itself, and should never replace full peer review. Please ensure you read the article fully alongside these and familiarize yourself with the tools and how they work, using the links provided below.

These reports are published under the terms of the [Creative Commons Attribution License](#)

### ITHENTICATE® REPORT

iThenticate® (<https://www.ithenticate.com>) checks the submitted article against an extensive database of articles from the internet and scholarly publications and highlights where similar sentences or phrases have been used previously, including in the author's own published work. Each individual match is given a percentage score based on how much it overlaps with the previously existing work, and an overall similarity score is given. The report generated from this are included here for transparency and can be cited independently using the DOI below.

- FAQs: <https://www.ithenticate.com/products/faqs>
- Help pages: <https://help.turnitin.com/ithenticate/ithenticate-user/ithenticate-user.htm#TheSimilarityReport>

### How to cite the iThenticate report for this article:

Watanabe R, Yoshida T, Nakaminami H. iThenticate report for: Virucidal activity of olanexidine gluconate against SARS-CoV-2. *Access Microbiology*. 2024. <https://doi.org/10.1099/acmi.0.000812.v1.1>

# ACMI-S-24-00071.pdf

*By* Hidemasa Nakaminami

---

WORD COUNT

2075

TIME SUBMITTED

05-MAR-2024 02:18PM

PAPER ID

107348218

**Access Microbiology**  
**Virucidal activity of olanexidine gluconate against SARS-CoV-2**  
--Manuscript Draft--

CONFIDENTIAL

1 *Access Microbiology*

2 Short Communication

3

4 **Virucidal activity of olanexidine gluconate against SARS-CoV-2**

5

6 Rika Watanabe<sup>a,1</sup>, Takuma Yoshida<sup>a,1</sup>, Hidemasa Nakamiami<sup>a,\*</sup>

7

8 <sup>4</sup>Department of Clinical Microbiology, School of Pharmacy, Tokyo University of

9 Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan

10

11 <sup>23</sup>Corresponding author. Department of Clinical Microbiology, School of Pharmacy,

12 Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo

13 192-0392, Japan. Tel.: +81-426-76-5642; Fax: +81-426-76-5647.

14 E-mail address: nakami@toyaku.ac.jp

15

16 <sup>1</sup>These authors contributed equally to this work.

17

18 **Abstract**

19 **20**  
**Introduction.**

20 **Antiseptics have been used for infection control** against SARS-CoV-2. Ethanol (EtOH)  
21 was effective against SARS-CoV-2, while chlorhexidine gluconate (CHG) was less  
22 effective. Therefore, there may be differences in virucidal activity between classes of  
23 antiseptic agents.

24 **Aim.**

25 **2**  
In this study, we evaluated the efficacy of antiseptics against SARS-CoV-2 and  
26 identified effective agents for infection control.

27 **Methods.**

28 The following antiseptics were used in this study: 1.5% olanexidine gluconate (OLG);  
29 80% EtOH; 1% sodium hypochlorite (NaClO); 0.2% benzalkonium chloride (BKC); 1%  
30 povidone-iodine (PVP-I); 0.5%, 1%, and 1.5% chlorhexidine gluconate (CHG); and 0.5%  
31 alkyldiaminoethylglycine hydrochloride (AEG). Virucidal activity was evaluated at 0, 30  
32 s, 1, 2, and 3 min according to EN14476.

33 **Results.**

34 After 30 s of exposure, 1.5% OLG, 80% EtOH, 1% NaClO, 0.2% BKC, and 1% PVP-  
35 I inactivated **2** SARS-CoV-2 below the detection limit. In contrast, the virus was survived

36 in 0.5% CHG, 1% CHG, and 0.5% AEG after 3 min of exposure. However, the virucidal  
37 activity of 1.5% CHG was insufficient after 30 s of exposure.

### 38 **Conclusion.**

39 This study showed that the <sup>5</sup>virucidal activity against SARS-CoV-2 differs depending  
40 on the class of antiseptic agent. Despite belonging to the same class of biguanide  
41 antiseptics, OLG was more effective <sup>7</sup>against SARS-CoV-2 than CHG.

### 43 **Keywords.**

44 SARS-CoV-2, antiseptics, olanexidine gluconate, <sup>13</sup>virucidal activity

### 46 **Abbreviations.**

47 SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; OLG, olanexidine  
48 gluconate; SARS-CoV-2<sup>WK-521</sup>, <sup>15</sup>SARS-CoV-2 JPN/TY/WK-521/2020 strain; EtOH,  
49 ethanol; NaClO, sodium hypochlorite; BKC, <sup>25</sup>benzalkonium chloride; PVP-I, povidone  
50 iodine; CHG, chlorhexidine gluconate; AEG, alkyldiaminoethylglycine hydrochloride;  
51 TCID<sub>50</sub>, Median Tissue Culture Infectious Dose; CPE, cytopathic effect.

52

53 **Introduction**

54 <sup>11</sup> Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was isolated from  
55 Wuhan, China, in 2019 [1]. SARS-CoV-2 is thought to have spread through contact and  
56 droplet transmission. Therefore, the appropriate use of an effective antiseptic agents is  
57 important for infection control [2, 3]. Antiseptic agents are classified based on their  
58 antimicrobial spectra as having high, medium, or low virucidal activity. High-level  
59 antiseptics are used to disinfect medical devices, such as endoscopes, and medium-level  
60 antiseptics are used to disinfect the environment, skin, and hands. Low-level <sup>14</sup> antiseptics  
61 are used to disinfect wounds, mucous membranes, and the environment. In 2015,  
62 oranexidine gluconate (OLG) was launched in Japan as a biguanide surgical field  
63 disinfectant [4]. OLG has strong virucidal activity against bacteria, including  
64 *Staphylococcus aureus*, *Pseudomonas aeruginosa*, human coronaviruses and influenza  
65 viruses [4, 5]. The SARS-CoV-2 has a lipid envelope that renders it susceptible to alcohol-  
66 based antiseptic agents [2]. In contrast, chlorhexidine gluconate (CHG), a biguanide  
67 disinfectant, was less effective against SARS-CoV-2 [2]. Therefore, there may be  
68 differences in virucidal activity between classes of antiseptic agents. <sup>2</sup> In this study, we  
69 evaluated the efficacy of antiseptics against SARS-CoV-2 and identified effective agents  
70 for infection control.

71

## 72 **Methods**

73 <sup>8</sup> SARS-CoV-2 JPN/TY/WK-521/2020 strain (SARS-CoV-2<sup>WK-521</sup>) was obtained from  
74 the National Institute of Infectious Diseases (Tokyo, Japan). VeroE6/TMPRSS2 cell  
75 (JCRB1819) were purchased from the Institute <sup>19</sup> of Biomedical Innovation, Health, and  
76 Nutrition (Osaka, Japan). VeroE6/TMPRSS2 cells were maintained in VP-SFM (GIBCO,  
77 Nebraska, USA) <sup>7</sup> supplemented with 200 mM L-glutamine, 100 units/mL penicillin and  
78 100 µg/mL streptomycin. The following antiseptics were included in this study at  
79 clinically used concentrations: <sup>9</sup> 1.5% OLG (Otsuka Pharmaceutical Factory, Inc.,  
80 Tokushima, Japan), <sup>6</sup> 80% ethanol (EtOH; FUJIFILM Wako Pure Chemical Corp.), 1%  
81 sodium hypochlorite (NaClO; <sup>6</sup> FUJIFILM Wako Pure Chemical Corp.), 0.2%  
82 benzalkonium chloride (BKC; <sup>6</sup> FUJIFILM Wako Pure Chemical Corp.), 1% povidone  
83 iodine (PVP-I; Sigma-Aldrich Co. LLC, Missouri, USA), 0.5%, 1%, and 1.5%  
84 chlorhexidine gluconate (CHG; <sup>6</sup> FUJIFILM Wako Pure Chemical Corp.) and 0.5%  
85 alkyldiaminoethylglycine hydrochloride (AEG; FUJIFILM Wako Pure Chemical Corp.).

86 The virucidal <sup>1</sup> test was conducted under clean conditions without interfering substances  
87 according to EN14476 [6]. An aliquot of 50 <sup>3</sup> µL of test virus was mixed with 450 µL of  
88 the test substances (or HEPES buffer as a negative control), and the samples were



89 incubated for 0, 30 sec, 1, 2 and 3 min at room temperature. No interfering substances  
90 were used in this study, and the test substances were diluted with distilled water. After  
91 incubation, the antiseptics were removed by gel filtration [6]. For the gel filtration method,  
92 100  $\mu$ L of the samples were diluted with 900  $\mu$ L of PBS and filtered through a gel filtration  
93 column (Columns filled with Sephacryl S-400; Cytiva, Tokyo, Japan). The filtrates were  
94 then serially diluted 10-fold with the culture media. Viral titers [ $\log_{10}$  Median Tissue  
95 Culture Infectious Dose (TCID<sub>50</sub>)/mL] in all antiseptics were measured by quantitative  
96 assays of six wells per dilution and three biological replicates and were determined by the  
97 Spearman–Kärber method [6]. The  $\log_{10}$  reductions in viral titers were calculated, and the  
98 results were expressed as the mean of the  $\log_{10}$  TCID<sub>50</sub>/mL  $\pm$  standard deviation.

99

## 100 Results

101 A comparison of the virucidal activities of the antiseptic agents showed that 1.5% OLG,  
102 80% EtOH, 1% NaClO, 0.2% BKC, and 1% PVP-I inactivated SARS-CoV-2 to below  
103 the detection limit after 30 s of exposure (Fig. 1). In contrast, the virus survived in 0.5%  
104 CHG, 1% CHG, and 0.5% AEG after 3 min of exposure. Although the virucidal activity  
105 of 1.5% CHG was insufficient after 30 s of exposure, the virus was reduced below the  
106 detection limit after 1 min of exposure.

107 Cell morphology was maintained by inactivating the virus with 1.5% OLG, 80% EtOH,  
108 1% NaClO, 0.2% BKC, and 1% PVP-I for 30 s (Fig. 2A, B). In contrast, cytotoxic effects  
109 (CPE) were observed when the virus was exposed to 0.5% CHG, 1% CHG, and 0.5%  
110 AEG for 30 s and 3 min, respectively, owing to insufficient virucidal activity. Consistent  
111 with virucidal activity, cell morphology was maintained by 1.5% CHG with 3 min  
112 exposure to the virus, whereas 30 s exposure was insufficient, and CPE was observed.

113

#### 114 Discussion

115 This study showed that OLG, EtOH, NaClO, BKC, and PVP-I were highly effective  
116 antiseptic agents against SARS-CoV-2. EtOH is an effective antiseptic agent <sup>17</sup> against  
117 SARS-CoV-2 [7]. EtOH is most commonly used for hand hygiene because of its fast-  
118 acting properties and is also used in hospitals to disinfect medical equipment, although it  
119 is not expected to have a long-lasting effect owing to its high volatility. NaClO, which is  
120 mainly used to disinfect medical devices, volatilizes its components in a short time.  
121 <sup>16</sup> SARS-CoV-2 has been reported to survive for long periods on various surfaces, including  
122 human skin and materials [8, 9]. Therefore, disinfection with EtOH or NaClO is likely to  
123 allow SARS-CoV-2 to survive if it is dried over time. In contrast, BKC and PVP-I are  
124 reported to be highly persistent and have long-lasting effect [10]. Thus, the effectiveness

125 of disinfectants varies greatly depending on their persistence on object surfaces. Further  
126 <sup>21</sup> studies should be conducted to determine the effectiveness of disinfectants on a variety  
127 of surfaces.

128 The virucidal activities of CHG and AEG were lower than those of other antiseptic  
129 agents used in this study. Low virucidal activity of CHG against SARS-CoV-2 has been  
130 reported [2]. This study is consistent with a previous study and shows that AEG has low  
131 <sup>5</sup> virucidal activity against SARS-CoV-2. The virucidal activity of CHG increased in a  
132 concentration-dependent manner, although the virus survived even at 1.5% CHG, which  
133 was the maximum concentration used in this study. Despite belonging to the same class  
134 of biguanide antiseptics, OLG was more effective against SARS-CoV-2 than CHG.  
135 However, they are structurally slightly different; CHG is a divalent cationic compound,  
136 whereas OLG is a monovalent cationic compound [4]. Therefore, it is possible that the  
137 difference in the charges of the compounds affects their virucidal activity. <sup>24</sup> Further studies  
138 are required to clarify the differences in the mechanisms of action of CHG and OLG  
139 against SARS-CoV-2 infection.

140 In this study, various antiseptic agents were evaluated at the maximum concentrations  
141 used in clinical settings. The results showed that most antiseptic agents inactivated SARS-  
142 <sup>2</sup> CoV-2 below the detection limit. The appropriate concentrations of antiseptic agents

143 depend on their intended use. Therefore, the evaluation of virucidal activity at low  
144 concentrations may reveal more detailed differences between antiseptic agents.

145

#### 146 **Conclusion**

147 The <sup>5</sup>virucidal activity against SARS-CoV-2 differs depending on the class of antiseptic  
148 agents. Despite belonging to the same class of biguanide antiseptics, OLG was more  
149 effective against SARS-CoV-2 than CHG. Therefore, appropriate antiseptic agents should  
150 be selected to SARS-CoV-2 infection control.

151

#### 152 **Funding information.**

153 <sup>12</sup>This work was supported by the Otsuka Pharmaceutical Factory, Inc.

154

#### 155 **Conflicts of interest.**

156 The authors (T. Y and H. N) have financial conflicts of interest with Otsuka  
157 Pharmaceutical Factory, Inc. as joint research funders.

158

159 **References**

- 160 1. Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ et al. Coronavirus Disease 2019 (COVID-  
161 19): A Perspective from China. *Radiology* 2020;296(2):E15-e25.
- 162 2. Viana Martins CP, Xavier CSF, Cobrado L. Disinfection methods against SARS-  
163 CoV-2: a systematic review. *The Journal of hospital infection* 2022;119:84-117.
- 164 3. Janik E, Bartos M, Niemcewicz M, Gorniak L, Bijak M. SARS-CoV-2: Outline,  
165 Prevention, and Decontamination. *Pathogens (Basel, Switzerland)* 2021;10(2).
- 166 4. Hagi A, Iwata K, Nii T, Nakata H, Tsubotani Y et al. Bactericidal Effects and  
167 Mechanism of Action of Olanexidine Gluconate, a New Antiseptic. *Antimicrobial*  
168 *agents and chemotherapy* 2015;59(8):4551-4559.
- 169 5. Imai K, Hagi A, Yamagawa S, Sano D. Olanexidine gluconate formulations as  
170 environmental disinfectants for enveloped viruses infection control. *The Journal of*  
171 *hospital infection* 2021;112:37-41.
- 172 6. EN14476. Chemical disinfectants and antiseptics - Quantitative suspension test for  
173 the evaluation of virucidal activity in the medical area -Test method and requirements  
174 (Phase 2/Step 1). 2013.
- 175 7. Singh D, Joshi K, Samuel A, Patra J, Mahindroo N. Alcohol-based hand sanitisers as  
176 first line of defence against SARS-CoV-2: a review of biology, chemistry and

- 177 formulations. *Epidemiology and infection* 2020;148:e229.
- 178 8. Chin AWH, Chu JTS, Perera MRA, Hui KPY, Yen HL et al. Stability of SARS-CoV-  
179 2 in different environmental conditions. *The Lancet Microbe* 2020;1(1):e10.
- 180 9. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A et al. Aerosol  
181 and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *The New*  
182 *England journal of medicine* 2020;382(16):1564-1567.
- 183 10. Hirose R, Itoh Y, Ikegaya H, Miyazaki H, Watanabe N et al. Evaluation of the  
184 Residual Disinfection Effects of Commonly Used Skin Disinfectants against Viruses:  
185 An Innovative Contact Transmission Control Method. *Environmental science &*  
186 *technology* 2021;55(23):16044-16055.

187 **Figure legends**

188 Fig. 1. Virucidal activity of antiseptic agents against SARS-CoV-2<sup>WK-521</sup>.

189

190 Fig. 2. Phase contrast image of VeroE6/TMPRSS2 after 30 s (A) and 3 min (B) of

191 antiseptic exposure.

CONFIDENTIAL

[Click here to access/download](#)

**Figure (only used for published Version of Record)**  
Fig. 1.pptx

CONFIDENTIAL



[Click here to access/download](#)

**Figure (only used for published Version of Record)**  
Fig. 2.pptx

CONFIDENTIAL

# 26%

SIMILARITY INDEX

---

### PRIMARY SOURCES

---

- 1** K. Imai, A. Hagi, S. Yamagawa, D. Sano. "Olanexidine gluconate formulations as environmental disinfectants for enveloped viruses infection control", *Journal of Hospital Infection*, 2021 61 words — 3%  
Crossref

---
- 2** Noritoshi Hatanaka, Bingting Xu, Mayo Yasugi, Hirofumi Morino et al. "Chlorine dioxide is a more potent antiviral agent against SARS-CoV-2 than sodium hypochlorite", *Journal of Hospital Infection*, 2021 46 words — 3%  
Crossref

---
- 3** Kaoru Imai, Akifumi Hagi, Sachi Yamagawa, Daisuke Sano. "Olanexidine gluconate formulations as environmental disinfectants for enveloped viruses infection control", *Journal of Hospital Infection*, 2021 44 words — 2%  
Crossref

---
- 4** [www.omicsonline.org](http://www.omicsonline.org) 41 words — 2%  
Internet

---
- 5** James Gitau Komu, Dulamjav Jamsransuren, Sachiko Matsuda, Haruko Ogawa, Yohei Takeda. "Efficacy Validation of SARS-CoV-2-Inactivation and Viral Genome Stability in Saliva by a Guanidine Hydrochloride and Surfactant-Based Virus Lysis/Transport Buffer", *Viruses*, 2023 26 words — 1%  
Crossref

- 
- 6 Yuki Tamura, Karina Kouzaki, Takaya Kotani, Koichi Nakazato. "Electrically stimulated contractile activity-induced transcriptomic responses and metabolic remodeling in C C myotubes: twitch vs. tetanic contractions ", American Journal of Physiology-Cell Physiology, 2020  
Crossref 25 words — 1%
- 
- 7 [www.mdpi.com](http://www.mdpi.com)  
Internet 24 words — 1%
- 
- 8 [mdpi-res.com](http://mdpi-res.com)  
Internet 22 words — 1%
- 
- 9 [tohoku.repo.nii.ac.jp](http://tohoku.repo.nii.ac.jp)  
Internet 20 words — 1%
- 
- 10 Archi Agrawal, Venkatesh Rangarajan, Sneha Shah, Ameya Puranik, Nilendu Purandare. "MIBG (Metaiodobenzylguanidine) Theranostics in pediatric and adult malignancies", The British Journal of Radiology, 2018  
Crossref 16 words — 1%
- 
- 11 [pure.uva.nl](http://pure.uva.nl)  
Internet 16 words — 1%
- 
- 12 Shoji Seyama, Hisae Nishioka, Hidemasa Nakaminami, Keisuke Nakase, Takeaki Wajima, Akifumi Hagi, Norihisa Noguchi. "Evaluation of *in Vitro* Bactericidal Activity of 1.5% Olanexidine Gluconate, a Novel Biguanide Antiseptic Agent", Biological and Pharmaceutical Bulletin, 2019  
Crossref 11 words — 1%
- 
- 13 [www.researchsquare.com](http://www.researchsquare.com)  
Internet 11 words — 1%

---

14 D. N. Payne, J. R. Babb, C. R. Bradley. " An evaluation of the suitability of the European suspension test to reflect activity of antiseptics against clinically significant organisms ", Letters in Applied Microbiology, 2002 9 words — < 1%

Crossref

---

15 Qing Hu, Yuan Xiong, Guang-Hao Zhu, Ya-Ni Zhang, Yi-Wen Zhang, Ping Huang, Guang-Bo Ge. " The SARS-CoV-2 main protease (M<sub>pro</sub>): Structure, function, and emerging therapies for COVID-19 ", MedComm, 2022 9 words — < 1%

Crossref

---

16 [ncceh.ca](https://ncceh.ca) 9 words — < 1%

Internet

---

17 [www.cambridge.org](https://www.cambridge.org) 9 words — < 1%

Internet

---

18 [www.wjgnet.com](https://www.wjgnet.com) 9 words — < 1%

Internet

---

19 Kaoru Imai, Makoto Tanaka, Seiji Miyoshi, Ren Murakami, Akifumi Hagi, Sachi Yamagawa, Daisuke Sano. "Disinfection efficacy and mechanism of olanexidine gluconate against norovirus", American Journal of Infection Control, 2021 8 words — < 1%

Crossref

---

20 Lalit Khare, Ratnesh Jain, Prajakta Dandekar. "Alternate synthesis of Olanexidine base employing phase transfer catalysis", Journal of the Indian Chemical Society, 2021 8 words — < 1%

Crossref

---

21 Liva Checkmahomed, Blandine Padey, Andrés Pizzorno, Olivier Terrier et al. "In Vitro 8 words — < 1%

## Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses", *Viruses*, 2020

[Crossref](#)

22 Paulo R. Souza, Camila F. Freitas, Junko Tsukamotoe, Gislaine S. Jacinto et al. "Enhanced cytocompatible gelatin/chondroitin sulfate/ionic liquid polyelectrolyte multilayers with virucidal activity against mouse hepatitis coronavirus", *Journal of Molecular Liquids*, 2024

8 words — < 1%

[Crossref](#)

23 Takaaki Koma, Naoya Doi, Akihiro Suzuki, Kentaro Nagamatsu et al. "Major target for UV-induced complete loss of HIV-1 infectivity: A model study of single-stranded RNA enveloped viruses", *Frontiers in Virology*, 2022

8 words — < 1%

[Crossref](#)

24 K. Ishimoto, N. Hatanaka, S. Otani, S. Maeda, B. Xu, M. Yasugi, J.E. Moore, M. Suzuki, S. Nakagawa, S. Yamasaki. "Tea crude extracts effectively inactivate severe acute respiratory syndrome coronavirus 2", *Letters in Applied Microbiology*, 2021

7 words — < 1%

[Crossref](#)

25 Naoto Watanabe, Ryohei Hirose, Katsuma Yamauchi, Hajime Miyazaki et al. "Evaluation of Environmental Stability and Disinfectant Effectiveness for Human Coronavirus OC43 on Human Skin Surface", *Microbiology Spectrum*, 2023

6 words — < 1%

[Crossref](#)

26 Shin-ichiro Hattori, Nobuyo Higshi-Kuwata, Jakka Raghavaiah, Debananda Das et al. "GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection", *mBio*, 2020

6 words — < 1%

[Crossref](#)

---

EXCLUDE QUOTES      OFF

EXCLUDE BIBLIOGRAPHY   ON

EXCLUDE SOURCES      OFF

EXCLUDE MATCHES      OFF